ConductScience.org, home

Trial · NCT01205529

ST-segment Elevation as an AF Endophenotype

NCT01205529, Not applicable, Completed, Vanderbilt University Medical Center; results first posted 2018-05-02

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. ST-segment Elevation as an AF Endophenotype. Trials, record NCT01205529. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01205529

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
ST-segment Elevation as an AF Endophenotype
NCT number
NCT01205529
Status
Completed
Phases
Not applicable
Enrollment
161 participants, actual
Lead sponsor
Vanderbilt University Medical Center
Conditions
Atrial Fibrillation
Interventions
Procainamide
First posted
2010-09-20
Last updated
2018-05-02
Results first posted
2018-05-02

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous ProcainamideDuring (5, 10, 15, 20, 25, 30 minutes after initiating) or up to 15 minutes after completion of intravenous procainamide infusionNumber of participants who demonstrated ST-segment elevation \>1.5mm in the right precordial leads (V1-V3) either at baseline or after sodium channel block with intravenous procainamide infusion.

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous ProcainamideDuring (5, 10, 15, 20, 25, 30 minutes after initiating) or up to 15 minutes after completion of intravenous procainamide infusionNumber of subject who had \>/= 1.5mm right precordial ST-segment elevation at baseline or with procainamide administrationParticipantsCOUNT_OF_PARTICIPANTS

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous ProcainamideAtrial Fibrillation With ST Changes on Electrocardiogram4Participants

Participant flow3

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDAtrial Fibrillation With ST Changes on Electrocardiogram161
Overall StudyCOMPLETEDAtrial Fibrillation With ST Changes on Electrocardiogram106
Overall StudyNOT COMPLETEDAtrial Fibrillation With ST Changes on Electrocardiogram55

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherHypotensionBlood and lymphatic system disordersAtrial Fibrillation With ST Changes on Electrocardiogram11061
otherNause/VomitingGastrointestinal disordersAtrial Fibrillation With ST Changes on Electrocardiogram41064
otherProlonged QTCardiac disordersAtrial Fibrillation With ST Changes on Electrocardiogram11061
seriousCerebrovascular accident (CVA) post ablationNervous system disordersAtrial Fibrillation With ST Changes on Electrocardiogram11061

Adverse event totals3

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityAtrial Fibrillation With ST Changes on Electrocardiogram
Total, other adverse eventsAtrial Fibrillation With ST Changes on Electrocardiogram6106
Total, serious adverse eventsAtrial Fibrillation With ST Changes on Electrocardiogram1106

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal years
U19HL065962Pharmacogenomics of Arrhythmia TherapyRODEN, DAN MVANDERBILT UNIVERSITY MEDICAL CENTERNATIONAL HEART, LUNG, AND BLOOD INSTITUTE2010 to 2014

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01205529

GET https://conductscience.org/api/trials/v1/NCT01205529/registered